Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (1-10 of 437) with videos related to

Pageof 44
Sort By:
Expert Review of Anticancer Therapy|June 18, 2010
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyondMartin Reck
Expert Review of Anticancer Therapy|April 2, 2015
Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitorMartin Reck
Expert Opinion on Investigational Drugs|May 15, 2010
BIBF 1120 for the treatment of non-small cell lung cancerMartin Reck
Expert Review of Anticancer Therapy|April 21, 2009
Gefitinib in the treatment of advanced non-small-cell lung cancerMartin Reck
Targeted Oncology|September 16, 2010
Examining the safety profile of angiogenesis inhibitors: implications for clinical practiceMartin Reck
Immunotherapy|November 18, 2017
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancerMartin Reck
Anticancer Research|July 22, 2005
Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)Martin Reck
Future Oncology (London, England)|March 25, 2006
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLCMartin Reck
Onkologie|September 25, 2007
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case seriesMartin Reck
Biologics : Targets & Therapy|July 15, 2015
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibMartin Reck, Anders Mellemgaard
Pageof 44

Showing results (1-10 of 437) with videos related to

Sort By:
Pageof 44
Expert Review of Anticancer Therapy|June 18, 2010
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyondMartin Reck
Expert Review of Anticancer Therapy|April 2, 2015
Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitorMartin Reck
Expert Opinion on Investigational Drugs|May 15, 2010
BIBF 1120 for the treatment of non-small cell lung cancerMartin Reck
Expert Review of Anticancer Therapy|April 21, 2009
Gefitinib in the treatment of advanced non-small-cell lung cancerMartin Reck
Targeted Oncology|September 16, 2010
Examining the safety profile of angiogenesis inhibitors: implications for clinical practiceMartin Reck
Immunotherapy|November 18, 2017
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancerMartin Reck
Anticancer Research|July 22, 2005
Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)Martin Reck
Future Oncology (London, England)|March 25, 2006
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLCMartin Reck
Onkologie|September 25, 2007
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case seriesMartin Reck
Biologics : Targets & Therapy|July 15, 2015
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibMartin Reck, Anders Mellemgaard
Pageof 44